Predicting Response to EGFR Inhibitors in Metastatic Colorectal Cancer: Current Practice and Future Directions

  • Shankaran V
  • Obel J
  • Benson A
29Citations
Citations of this article
50Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The identification of KRAS mutational status as a predictive marker of response to antibodies against the epidermal growth factor receptor (EGFR) has been one of the most significant and practice-changing recent advances in colorectal cancer research. Recently, data suggesting a potential role for other markers (including BRAF mutations, loss of phosphatase and tensin homologue deleted on chromosome ten expression, and phosphatidylinositol-3-kinase–AKT pathway mutations) in predicting response to anti-EGFR therapy have emerged. Ongoing clinical trials and correlative analyses are essential to definitively identify predictive markers and develop therapeutic strategies for patients who may not derive benefit from anti-EGFR therapy. This article reviews recent clinical trials supporting the predictive role of KRAS, recent changes to clinical guidelines and pharmaceutical labeling, investigational predictive molecular markers, and newer clinical trials targeting patients with mutated KRAS.

Cite

CITATION STYLE

APA

Shankaran, V., Obel, J., & Benson, A. B. (2010). Predicting Response to EGFR Inhibitors in Metastatic Colorectal Cancer: Current Practice and Future Directions. The Oncologist, 15(2), 157–167. https://doi.org/10.1634/theoncologist.2009-0221

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free